Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. viral disease
Show results for
Products
Services
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Viral Disease Articles & Analysis

38 news found

Protheragen Announces Vaccine Development Services Targeting Rare Infectious Diseases

Protheragen Announces Vaccine Development Services Targeting Rare Infectious Diseases

Infectious diseases are disorders caused by organisms — such as bacteria, viruses, or parasites. A vaccine is a specialized biological formulation that triggers the immune system to recognize and activate protective responses against specific disease-causing agents. With the global landscape of infectious diseases continually evolving, ...

ByProtheragen


Influenza A Virus Mouse Models for Accelerated Research

Influenza A Virus Mouse Models for Accelerated Research

These variations are driven by RNA polymerase as it replicates the viral genome. In addition, when different subtypes infect the same host cell, genetic recombination occurs between them to further generate new strains of the virus. ...

ByCreative Diagnostics


Advanced Lung Function Measurement In A Novel HIV/Tuberculosis Co-Infection Mouse Model

Advanced Lung Function Measurement In A Novel HIV/Tuberculosis Co-Infection Mouse Model

Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) are major global health threats. Their interaction worsens disease severity, as HIV reduces CD4+ T cells, making individuals more vulnerable to TB. ...

BySCIREQ - an emka TECHNOLOGIES Company


Fungal Disease Awareness Week and Protecting Patients, Workers and Building Occupants from Exposure Risks

Fungal Disease Awareness Week and Protecting Patients, Workers and Building Occupants from Exposure Risks

Fungal Disease Awareness Week (FDAW) kicks off today and runs through the 22nd. The Centers for Disease Control and Prevention (CDC) created FDAW to highlight the importance of recognizing, treating, and preventing serious fungal diseases. ...

ByCochrane & Associates, LLC


Exclusive License Agreement With Case Western Reserve University for Core-NK Platform (Supplementary Announcement)

Exclusive License Agreement With Case Western Reserve University for Core-NK Platform (Supplementary Announcement)

Chimeric also receives exclusive global rights to the CORE-NK platform for immune disorders and viral infectious diseases. Chimeric’s exclusive global license from CWRU covers patent rights, knowhow, and biological materials in relation to therapeutic products for the NKF feeder cell line and CORE-NK manufacturing process in the fields of use, including ...

ByChimeric Therapeutics


Exclusive License Agreement With Case Western Reserve University for Core-NK Platform

Exclusive License Agreement With Case Western Reserve University for Core-NK Platform

Chimeric also receives exclusive global rights to the CORE-NK platform for immune disorders and viral infectious diseases. “We are excited to continue building on our collaboration with CWRU with the definitive license agreement for the CORE-NK platform,” said Jennifer Chow, CEO and Managing Director of Chimeric. ...

ByChimeric Therapeutics


XPhyto Signs Letter of Intent for US Manufacturing and Strategic Business Opportunities

XPhyto Signs Letter of Intent for US Manufacturing and Strategic Business Opportunities

XPhyto’s pipeline of biosensor screening products for inflammatory, bacterial and viral infectious diseases includes stomatitis, periimplantitis, periodontitis, group A strep, influenza A, and covid-19. ...

ByXPhyto Therapeutics Corporation


XPhyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-related Dental Disease

XPhyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-related Dental Disease

The company expects to provide further updates on its oral health and infectious disease screening test programs in the coming weeks. XPhyto’s pipeline of biosensor screening products for inflammatory, bacterial and viral infectious diseases includes stomatitis, periimplantitis, periodontitis, group A strep, influenza A, and covid-19. ...

ByXPhyto Therapeutics Corporation


Breaking News! Reetoo Monkeypox Virus Real Time PCR Kit

Breaking News! Reetoo Monkeypox Virus Real Time PCR Kit

According to the report of World Health Organization (WHO) on May 21, more than 120 confirmed or suspected cases of monkeypox, a rare viral disease seldom detected outside Africa, have been reported in at least 12 non-epidemic countries around the world, including more than 20 confirmed cases in Portugal, Spain and the UK. ...

ByShenzhen Reetoo Biotechnology Co.,Ltd


Nature publication: Ondine’s therapy suppresses SARS2 in COVID-19 patients

Nature publication: Ondine’s therapy suppresses SARS2 in COVID-19 patients

The Toronto-based research reports a decrease of viral infectivity of 90% of SARS-CoV-2 patient samples using Ondine’s nasal antimicrobial photodynamic disinfection (aPDT), with 70% of patient samples completely inactivated from a single 5-minute treatment. ...

ByOndine Biomedical Inc


AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients

AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients

At baseline, 34 patients had a viral load below 10,000 copies/mL. The median viral load in these 34 patients was 2,042 copies/mL on Day 1. ...

ByKalaris


OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases

OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases

The ModeX product portfolio includes cancer immunotherapies that combine four specificities into one protein to improve targeting and immune killing, as well as masking or “stealth” technology to improve tumor-specific killing and reduce side effects. For viral diseases, the lead targets of a broad and potent multi-specific antibody portfolio include ...

ByOPKO Health, Inc.


AlloVir Reports First Quarter 2022 Financial Results

AlloVir Reports First Quarter 2022 Financial Results

As 90% of allo-HCT patients reactivate at least one of these viruses, there is a large global market opportunity for the prevention of devastating viral diseases, with an estimated addressable patient population of 40,000 allo-HCT patients annually. ...

ByKalaris


FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients

Posoleucel has the potential to fundamentally transform the landscape for allo-HCT by preventing life-threatening viral diseases and infections, either as a prophylactic therapy in high-risk patients or as a preemptive therapy in patients who have already reactivated one or more of the six viruses targeted by posoleucel. As 90% of allo-HCT patients reactivate at ...

ByKalaris


AlloVir Appoints Shawn Tomasello to Its Board of Directors

AlloVir Appoints Shawn Tomasello to Its Board of Directors

About AlloVir AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T ...

ByKalaris


AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant Patients

AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant Patients

As 90% of allo-HCT patients reactivate at least one of these viruses, there is a large global market opportunity for the prevention of devastating viral diseases, with an estimated addressable patient population of 40,000 allo-HCT patients annually. ...

ByKalaris


HTI announces Dr. Doug Kawahara as Senior Advisor for AI/ML Drug Discovery

HTI announces Dr. Doug Kawahara as Senior Advisor for AI/ML Drug Discovery

Prior to that, he was Vice President, Business Development, at Receptor BioLogix (Palo Alto, CA), a biopharmaceutical company focused on the discovery and development of novel biotherapeutics for the treatment of cancer and autoimmune diseases, Senior Director, Business Development, at Anesiva, Inc. (fka Corgentech, South San Francisco, CA), a developer of drugs for treating pain ...

ByHealth Technology Innovations, Inc.


Our Alliance with Serum Institute Provides an Accelerated Entry into Vaccines

Our Alliance with Serum Institute Provides an Accelerated Entry into Vaccines

Dr Arun Chandavarkar, Managing Director, Biocon Biologics Ltd., says the structure of the strategic alliance with Serum Institute Life Sciences provides Biocon Biologics with an asset light and accelerated entry into the often overlooked infectious diseases segment. Having established capabilities and a track record of success in biologics, Biocon Biologics’ foray into ...

ByBiocon


AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

About AlloVir AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells ...

ByKalaris


AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook

AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook

The preliminary data set demonstrated a substantial reduction in the expected rate of clinically significant viral infections or diseases and facilitates an accelerated path to Phase 3 development, which has been agreed to in principle by the U.S. ...

ByKalaris

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT